PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Caulier, B.* ; Joaquina, S.* ; Gelebart, P.* ; Dowling, T.H.* ; Kaveh, F.* ; Thomas, M. ; Tandaric, L.* ; Wernhoff, P.* ; Katyayini, N.U.* ; Wogsland, C.* ; Gjerstad, M.E.* ; Fløisand, Y.* ; Kvalheim, G.* ; Marr, C. ; Kobold, S. ; Enserink, J.M.* ; Gjertsen, B.T.* ; McCormack, E.* ; Inderberg, E.M.S.* ; Wälchli, S.*

CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia.

Cell Rep. Med. 5:101572 (2024)
Verlagsversion DOI
Open Access Gold
Creative Commons Lizenzvertrag
Acute myeloid leukemia (AML) is characterized by the accumulation of immature myeloid cells in the bone marrow and the peripheral blood. Nearly half of the AML patients relapse after standard induction therapy, and new forms of therapy are urgently needed. Chimeric antigen receptor (CAR) T therapy has so far not been successful in AML due to lack of efficacy and safety. Indeed, the most attractive antigen targets are stem cell markers such as CD33 or CD123. We demonstrate that CD37, a mature B cell marker, is expressed in AML samples, and its presence correlates with the European LeukemiaNet (ELN) 2017 risk stratification. We repurpose the anti-lymphoma CD37CAR for the treatment of AML and show that CD37CAR T cells specifically kill AML cells, secrete proinflammatory cytokines, and control cancer progression in vivo. Importantly, CD37CAR T cells display no toxicity toward hematopoietic stem cells. Thus, CD37 is a promising and safe CAR T cell AML target.
Impact Factor
Scopus SNIP
Altmetric
11.700
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Acute Myeloid Leukemia ; Aml ; Car T Cell ; Cd37 ; Chimeric Antigen Receptor ; Hematopoietic Stem Cell ; Immunotherapy ; Patient-derived Xenograft; Car T-cell; Antibody-drug Conjugate; Expression; Aml; Efficacy; Siglec-6; Therapy; Protein; Cancer
Sprache englisch
Veröffentlichungsjahr 2024
HGF-Berichtsjahr 2024
ISSN (print) / ISBN 2666-3791
e-ISSN 2666-3791
Zeitschrift Cell Reports Medicine
Quellenangaben Band: 5, Heft: 6, Seiten: , Artikelnummer: 101572 Supplement: ,
Verlag Cell Press
Verlagsort 50 Hampshire St, Floor 5, Cambridge, Ma 02139 Usa
Begutachtungsstatus Peer reviewed
Institut(e) Institute of AI for Health (AIH)
Unit for Clinical Pharmacology (KKG-EKLiP)
POF Topic(s) 30205 - Bioengineering and Digital Health
30203 - Molecular Targets and Therapies
Forschungsfeld(er) Enabling and Novel Technologies
Immune Response and Infection
PSP-Element(e) G-540007-001
G-522100-001
Förderungen Fritz Bender Foundation
Research Council of Norway
Norwegian Health Authority South-East
Norwegian Cancer Society
Research Council of Norway (NFR)
University of Bergen PhD fellowship
Marie Sklodowska-Curie Program Training Network for Optimizing Adoptive T Cell Therapy of Cancer - H2020 Program of the European Union
Hector Foundation
Deutsche Forschungsge-meinschaft (DFG)
European Research Council
Wilhelm Sander-Stiftung
Bayerische Forschungsstiftung
m4 award of the Bavarian Ministry for Economical Affairs
Go-Bio Initiative
Ernst-Jung-Stiftung
German Cancer Aid
Else Kroner-Fresenius-Stiftung
International Doctoral Program i-Target, Immunotargeting of Cancer - Elite Network of Bavaria
Childhood Cancer Society
DOI 10.1016/j.xcrm.2024.101572
WOS ID 001259361100001
Scopus ID 85194546743
Erfassungsdatum 2024-07-08
[➜Korrektur melden]